PrimaGen Holding B. V. – Trademark Portfolio

Entity Type: 10

PrimaGen Holding B. V. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 4 Nice Classification classes. The owner is based in 1105 BA Amsterdam.

Meibergdreef 59

1105 BA Amsterdam , NL

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

RETINA
RETINA
Cancelled 2003
PRIMAGEN
PRIMAGEN
Cancelled 2003
MITOX
MITOX
Cancelled 2003

Trademark Classifications

PrimaGen Holding B. V.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

1
Chemicals (3 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does PrimaGen Holding B. V. have?

PrimaGen Holding B. V. has 4 U.S. trademarks filed with the USPTO.

What trademark classes does PrimaGen Holding B. V. file in?

PrimaGen Holding B. V. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is PrimaGen Holding B. V.'s trademark registration success rate?

PrimaGen Holding B. V. has a 0% trademark registration rate, with 0 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.